Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
anticoagulant
Biotech
Blackstone's $250M bet beats Xarelto in phase 2 bleeding trial
Anthos’ abelacimab significantly cut bleeding compared to Bayer and J&J’s Xarelto, adding evidence it can stop clots without affecting hemostasis.
Nick Paul Taylor
Sep 18, 2023 6:00am
BMS, J&J's secondary stroke med doesn't stick the landing
Aug 28, 2022 3:36am
Racing Bayer, Merck gets FDA fast-track tag for anticoagulant
Aug 23, 2022 8:40am
Bayer-Ionis' anti-thrombotic med doesn't increase bleeding
Jul 28, 2022 10:51am
Amag merges with Perosphere, adding NOAC antidote
Dec 13, 2018 9:55am
Boston Sci to distribute Veniti’s venous stent
Sep 11, 2017 11:31am
